Drugs / VS-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06959082 | Jun 2026 → Jun 2027 expected | head and neck squamous cell carcinoma | VSPharmTech Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06959082 ↗ |